Acquisitions, Mergers & PartnershipsBiomaterialsBioprintingMedical AM

Prellis Biologics to provide human lymph node organoids for research

Partnering with Sanofi and leveraging the EXIS antibody discovery platform

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Prellis Biologics Inc., a biotherapeutics company with human tissue engineering capabilities, has entered into a collaboration and license option agreement with Sanofi S.A., an innovative global healthcare company. The collaboration will focus on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS), and leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs) and recreate immune responses in vitro to deliver antibodies with significant genetic diversity.

For their EXIS in vitro human antibody discovery, Prellis utilized its proprietary holographic printing technology to engineer lymph node organoids (LNOs) that mimic the human lymph node. The EXIS human antibody discovery platform is the first of its kind and significantly reduces discovery and lead identification time compared to existing in vivo or in vitro approaches. Prellis has challenged LNOs with a variety of target antigens in different formats to produce fully human antibody libraries with high affinities, sequence diversity and potency, ready for lead selection within 3 weeks. Additional applications of the EXIS platform currently include therapeutic screening and vaccine testing.

Prellis Biologics to collaborate with Sanofi on discovery of antibodies using EXIS antibody discovery platform and lymph node organoids

“The EXIS platform provides an unparalleled ability to recreate lymph node organoids in vitro. This powerful technology enables investigation of human B- and T-cell responses for a variety of applications, including antibody discovery and therapeutic immunogenicity,” said Melanie P. Matheu, PhD, Founder and CEO of Prellis Biologics. “We are delighted to work in collaboration with Sanofi in novel antibody research with our differentiated approach.”

“Recreating the human immune response and breaking tolerance to human antigens, in the EXIS platform allows us to rapidly identify an expansive set of high-quality antibodies,” said Kevin Chapman, PhD and CSO of Prellis.

Under the terms of the agreement, Prellis and Sanofi will collaborate on the generation of human antibodies for a target of interest. In return for an undisclosed up-front payment, Sanofi receives an exclusive option to license, develop and further commercialize the resulting antibodies.

Consumer Products AM 2024

This new market study from VoxelMatters provides an in-depth analysis and forecast of polymer and metal AM in the consumer products industry across the three core segments of the additive manufactu...

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.